Evidence map›Paper›PMID 39131875›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2024

Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy.

Erik J van Gennep, Francesco Claps, Peter J Bostrom, Shahrokh F Shariat, Yann Neuzillet, Alexandre R Zlotta, Carlo Trombetta, Markus Eckstein, Laura S Mertens, Rossana Bussani and 15 more

Abstract read
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Erik J van GennepDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Francesco ClapsDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Peter J BostromDepartment of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Shahrokh F ShariatDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yann NeuzilletDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Alexandre R ZlottaDepartment of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Carlo TrombettaDepartment of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy.
Markus EcksteinInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Laura S MertensDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Rossana BussaniDepartment of Pathology, University of Trieste, Trieste, Italy.
Maximilian BurgerDepartment of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
Joost L BoormansDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Bernd WullichDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Arndt HartmannInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Roman MayrDepartment of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
Nicola PavanDepartment of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy.
Riccardo BartolettiDepartment of Translational Research and New Technologies, Unit of Urology, University of Pisa, Pisa, Italy.
M Carmen MirDepartment of Urology, Hospital Universitario La Ribera, Valencia, Spain.
Damien PouesselMolecular Oncology Team, Institut Curie, CNRS, UMR144, PSL Research University, Paris, France.
John van der HoevenDepartment of Urology, Reinier de Graaf Hospital, Delft, The Netherlands.
Theo H van der KwastDepartment of Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Yves AlloryMolecular Oncology Team, Institut Curie, CNRS, UMR144, PSL Research University, Paris, France.
Tahlita C M ZuiverloonDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Yair LotanDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bas W G van RhijnDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed.

objectivesTo evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection.

methodsWe analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers. LN-densitywas calculated as the ratio of the number of positive LNs×100% to the number of LNs removed. The optimal LN-density cut-off value was defined by creating a time-dependent receiver operating characteristic (ROC) curve in pN patients. Univariable and multivariable Cox' regression analyses were used to assess the effect of conventional Tumor Nodes Metastasis (TNM) nodal staging system, LN-density and other LN-related variables on DSS in the pN-positive cohort.

resultsOf the 1169 patients, 463 (39.6%) patients had LN-involvement. The area under the ROC curve was 0.60 and the cut-off for LN-density was set at 20%, 223 of the pN-positive patients (48.2%) had a LN-density ≥ 20%. In multivariable models, the number of LN-metastases (HR 1.03, p = 0.005) and LN-density, either as continuous (HR 1.01, p = 0.013) or as categorical variable (HR 1.37, p = 0.014), were independently associated with worse DSS, whereas pN-stage was not.

conclusionsLN-density ≥ 20% was an independent predictor of worse DSS in BC patients with LN-involvement at RC. The integration of LN-density and other LN-parameters rather than only conventional pN-stage may contribute to a more refined risk-stratification in BC patients with nodal involvement.

Indexed as

Bladder cancerlymph node densityradical cystectomysurvivalurothelial neoplasm

Identifiers

PMID39131875
PMCPMC11308645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.